MetrioPharm's MP1032 Receives FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Treatment
核心洞察
MetrioPharm AG received FDA orphan drug designation for MP1032 to treat Duchenne muscular dystrophy (搜索), a rare genetic disorder affecting muscle function.
Preclinical studies showed MP1032 enhanced muscle strength comparable to corticosteroids but without serious side effects typically associated with standard treatments.
The company demonstrated that combining MP1032 with a 90% reduced dose of prednisolone achieved more than 2.5 times the efficacy of normal prednisolone dosing.
MetrioPharm AG announced that the U.S. Food and Drug Administration has granted orphan drug designation for MP1032 in the treatment of Duchenne muscular dystrophy (搜索) (DMD), marking a significant regulatory milestone for the Swiss pharmaceutical company's lead compound. The designation positions MP1032 for accelerated development pathways and provides crucial regulatory advantages for addressing this rare genetic disorder.
Addressing Critical Unmet Medical Need
DMD represents the most common form of muscular dystrophy, characterized by progressive muscle degeneration with symptom onset typically occurring between ages two and three. The genetic disorder primarily affects boys, causing severe muscle loss and heart failure, while girls may experience milder symptoms. Current standard therapies rely on high-dose corticosteroids administered for decades, which can only slow disease progression while causing serious side effects that significantly impact patients' quality of life.
"Currently, DMD cannot be cured, but it can be treated," said Dr. Wolfgang Brysch, MetrioPharm's Chief Scientific Officer and co-founder. "These treatments have serious side effects that heavily impact patients' quality of life. With MP1032 we aim to improve the tolerability of treatment while also further slowing down disease progression."
Promising Preclinical Results
MetrioPharm conducted preclinical studies in cooperation with patient organization Duchenne UK (搜索), testing MP1032 in an mdx model for DMD and comparing its effects to corticosteroids. The results demonstrated that MP1032 enhanced muscle strength comparable to the corticosteroid Prednisolone, but without the serious side effects associated with the standard treatment.
In a second preclinical study executed by Eurofins (搜索), researchers observed a remarkable synergistic effect when combining MP1032 with reduced corticosteroid dosing. The combination of MP1032 with a 90% reduced dose of Prednisolone increased efficacy to more than 2.5 times that of the normal Prednisolone dose alone. This supra-additive effect indicates that both substances are more effective in combination than either substance administered individually.
Regulatory Advantages and Development Timeline
The FDA orphan drug designation provides MetrioPharm with several development advantages, including assistance in the development process, exemptions from FDA fees, and seven years of post-approval marketing exclusivity. DMD affects fewer than 200,000 people in the United States, qualifying it as a rare disease under FDA criteria.
"The orphan drug designation is granted by the FDA for drug candidates that the FDA considers a promising new treatment," explained Thomas Christély, MetrioPharm's CEO. "In a designated orphan development, timelines are shorter, and costs are lower compared to indications with larger patient populations."
The company has also received orphan designation from the European Medicines Agency for the same indication, with the EMA granting orphan status on January 13, 2023. MetrioPharm plans to initiate a Phase II clinical trial in DMD in 2024, leveraging the regulatory support provided by both designations.
Broader Development Platform
MetrioPharm's approach centers on modulating immune metabolism through first-in-class self-regulating drug candidates. The company's platform has generated small-molecule metabolic modulators demonstrating preclinical and clinical efficacy across multiple inflammatory and infectious diseases with an outstanding safety profile.
Beyond DMD, MetrioPharm has obtained preclinical and clinical efficacy data in multiple sclerosis, arthritis, sepsis, inflammatory bowel disease, and psoriasis. The company recently completed a Phase IIa exploratory study in hospitalized COVID-19 patients, supported by a grant from the European Health Emergency Preparedness and Response Authority, which confirmed MP1032's clinical safety profile and demonstrated compelling efficacy data.